Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Amigo Mike who wrote (9790)	10/29/1998 8:02:00 PM
From: Ie Coan Bie	Read Replies (1) \| Respond to of 29382

Are you still following CYPB ? good news just released PROSORBA COLUMN RECOMMENDED FOR APPROVAL BY FDA ADVISORY PANEL F Business Wire October 29, 1998, 2:58 p.m. PT or Use in Rheumatoid Arthritis Business Editors, Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 1998-- Unique Treatment May Provide Non-Drug Alternative To Currently Available Therapies Conference Call Scheduled for Monday Cypress Bioscience, Inc. (NASDAQ: CYPB) announced today that the Prosorba(R) column was recommended for approval for the treatment of moderate to severe rheumatoid arthritis (RA) by the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Device Advisory Panel. The Panel voted ten to one in favor of this recommendation. The Panel recommended the approval of the Company's Pre-Market Application (PMA), which would extend labeling of the Prosorba(R) column to include RA, subject to the requirement that the Company conduct a post-marketing study. The column received FDA approval in 1987 for treatment of Idiopathic Thrombocytopenic Purpura (ITP), an immune-mediated bleeding disorder, and has been used safely for 11 years. For RA, the Prosorba(R) column would be used in moderate to severe patients who have failed second-line, or Disease Modifying Anti-Rheumatic Drugs (DMARDs), such as methotrexate. news.com and more good thing for CYPB is : There will be a Conference Call Scheduled for Monday, so buy on rumor and sell on news action will not happen tomorrow, it is important to maintain the stock price move up gradually, until CYPB get full approval from FDA. Do you have prediction, at what price this stock will be opened tomorrow ? Abi